Correction to: The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression ; volume:21 ; number:1 ; day:9 ; month:6 ; year:2021 ; pages:1 ; date:12.2021
Cancer cell international ; 21, Heft 1 (9.6.2021), 1, 12.2021
- Urheber
-
Tong, Dali
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-021-02010-x
- URN
-
urn:nbn:de:101:1-2021100207254917986354
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tong, Dali
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Ailanthone: a new potential drug for castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Ailanthone: a new potential drug for castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Ailanthone: a new potential drug for castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches